W.L. Gore & Associates

Mitico specializes in advanced carbon capture technology. Utilizing its patented granulated metal carbonate sorption process, developed at Caltech, Mitico removes over 95% of CO2 emissions from post-combustion sources such as gas-fired power plants and waste-to-energy facilities. This enables cost-effective carbon capture, utilization, and storage (CCUS) services.

Founded in Seattle in 2008, Arzeda specializes in protein design technology. It creates and manufactures proteins and enzymes for pharmaceuticals, industrial chemicals, polymers, and other advanced applications.

InnAVasc Medical, Inc., established in 2013 and headquartered in Durham, North Carolina, specializes in the design and development of medical devices for vascular access in hemodialysis. The company's primary product, the Bullet Proof Vascular Access Graft, is an arteriovenous graft featuring two multilayer cannulation chambers, engineered to resist posterior and sidewall needle penetration and injury, thereby enhancing the safety and longevity of vascular access for hemodialysis patients.

Founded in 2013 and based in Alpine, California, PhysioLogic Devices focuses on developing advanced implantable products aimed at transforming the treatment of insulin-requiring diabetes. The company's flagship technology is an implantable pump that delivers insulin to the intraperitoneal space, fully automating glucose control and normalizing physiology.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.

Quellan, Inc. is a designer and developer of analog signal processing and radio frequency noise cancellation integrated circuits (IC) based in Santa Clara, California. Founded in 2001, the company specializes in creating innovative solutions for various markets, including automotive, computing, data centers, storage, consumer electronics, and wireless applications. Quellan's product offerings include noise cancellers that detect and counteract unwanted noise in signal paths, system developer kits for mobile television and GPS, quad and single lane extenders for maintaining analog signal integrity in data center equipment, as well as evaluation boards, cable modules, and active cables. These products are utilized in a range of applications, such as active cables, linecards, backplanes, and mobile television systems. As of 2009, Quellan operates as a subsidiary of Intersil Corp.